Description: Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs.
Home Page: www.reparerx.com
RPTX Technical Analysis
7210 Frederick-Banting
Montreal,
QC
H4S 2A1
Canada
Phone:
857 412 7018
Officers
| Name | Title |
|---|---|
| Mr. Lloyd Mitchell Segal | Pres, CEO & Director |
| Mr. Steve Forte | Exec. VP & CFO |
| Dr. Michael Zinda Ph.D. | Exec. VP & Chief Scientific Officer |
| Dr. Maria Koehler M.D., Ph.D. | Exec. VP & Chief Medical Officer |
| Dr. Daniel Durocher Ph.D. | Co-Founder |
| Dr. Frank Sicheri Ph.D. | Co-Founder |
| Dr. Agnel Sfeir Ph.D. | Co-Founder |
| Mr. Cameron Black | Exec. VP of Discovery |
| Dr. Kim A. Seth Ph.D. | Exec. VP & Chief Bus. Officer |
| Mr. Philip Herman | Exec. VP of Commercial & New Product Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0392 |
| Price-to-Sales TTM: | 5.1987 |
| IPO Date: | 2020-06-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 168 |